VANCOUVER, Aug. 13 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI;
TSX: ANP), today announced that it has received approval to begin marketing
the Quill(TM) SRS Polydioxanone (PDO), MONODERM(TM), Polypropylene and Nylon
product lines in Brazil.
"We are very excited about the approval of the Quill SRS product lines in
Brazil, one of the largest surgical markets in the world. Quill has been
lauded in the U.S., Europe and Canada for the efficiency it brings to wound
closure. Now, Brazilian patients and surgeons in plastics, orthopedics and
gynecology can benefit from it as well," said Dr. William Hunter, President
and CEO of Angiotech.
The Quill SRS product lines include two absorbable sutures - MONODERM and
PDO, and two non-absorbable sutures - Polypropylene and Nylon, and are
approved for sale in the U.S., Europe, and Canada.
About the Quill(TM) Self-Retaining System (SRS)
Quill SRS represents a revolutionary technology in wound closure made
possible by bidirectional fixation within the wound. Its patented design
allows the surgeon to begin closure at the midpoint of the wound and suture in
two directions from the midpoint. Barbs within the Quill SRS distribute
tension across the wound and eliminate the need for knots.
Forward Looking Statements
Statements contained in this press release that are not based on
historical fact, including without limitation statements containing the words
"believes," "may," "plans," "will," "estimates," "continues," "anticipates,"
"intends," "expects" and similar expressions, constitute "forward-looking
statements" within the meaning of the Private Securities Litigation Reform Act
of 1995 and constitute "forward-looking information" within the meaning of
applicable Canadian securities laws. All such statements are made pursuant to
the "safe harbor" provisions of applicable securities legislation.
Forward-looking statements may involve, but are not limited to, comments with
respect to our objectives and priorities for the remainder of 2009 and beyond,
our strategies or future actions, our targets, expectations for our financial
condition and the results of, or outlook for, our operations, research and
development and product and drug development. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors that may
cause the actual results, events or developments to be materially different
from any future results, events or developments expressed or implied by such
forward-looking statements. Many such known risks, uncertainties and other
factors are taken into account as part of our assumptions underlying these
forward-looking statements and include, among others, the following: general
economic and business conditions in the United States, Canada and the other
regions in which we operate; market demand; technological changes that could
impact our existing products or our ability to develop and commercialize
future products; competition; existing governmental regulations and changes
in, or the failure to comply with, governmental regulations; availability of
financial reimbursement coverage from governmental and third-party payers for
products and related treatments; adverse results or unexpected delays in
pre-clinical and clinical product development processes; adverse findings
related to the safety and/or efficacy of our products or products sold by our
partners; decisions, and the timing of decisions, made by health regulatory
agencies regarding approval of our technology and products; the requirement
for substantial funding to conduct research and development, to expand
manufacturing and commercialization activities; and any other factors that may
affect our performance. In addition, our business is subject to certain
operating risks that may cause any results expressed or implied by the
forward-looking statements in this Quarterly Report on Form 10-Q to differ
materially from our actual results. These operating risks include: our ability
to attract and retain qualified personnel; our ability to successfully
complete pre-clinical and clinical development of our products; changes in our
business strategy or development plans; our failure to obtain patent
protection for discoveries; loss of patent protection resulting from
third-party challenges to our patents; commercialization limitations imposed
by patents owned or controlled by third parties; our ability to obtain rights
to technology from licensors; liability for patent claims and other claims
asserted against us; our ability to obtain and enforce timely patent and other
intellectual property protection for our technology and products; the ability
to enter into, and to maintain, corporate alliances relating to the
development and commercialization of our technology and products; market
acceptance of our technology and products; our ability to successfully
manufacture, market and sell our products; the availability of capital to
finance our activities; our ability to restructure and to service our debt
obligations; and any other factors referenced in our other filings with the
applicable Canadian securities regulatory authorities or the Securities and
Exchange Commission ("SEC"). For a more thorough discussion of the risks
associated with our business, see the "Risk Factors" section in our annual
report for the year ended December 31, 2008 filed with the SEC on Form 10-K,
and our quarterly report for the three months ended June 30, 2009 filed with
the SEC on Form 10-Q.
Given these uncertainties, assumptions and risk factors, investors are
cautioned not to place undue reliance on such forward-looking statements.
Except as required by law, we disclaim any obligation to update any such
factors or to publicly announce the result of any revisions to any of the
forward-looking statements contained in this press release to reflect future
results, events or developments.
(C)2009 Angiotech Pharmaceuticals, Inc. All Rights Reserved.
Quill(TM) is a trademark of Quill Medical, Inc., a wholly-owned
subsidiary of Angiotech Pharmaceuticals, Inc.
About Angiotech Pharmaceuticals
Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and
medical device company with over 1,500 dedicated employees. Angiotech
discovers, develops and markets innovative treatment solutions for diseases or
complications associated with medical device implants, surgical interventions
and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP),
please visit our website at www.angiotech.com.
For further information:
For further information: DeDe Sheel, Investor Relations and Corporate
Communications, Angiotech Pharmaceuticals, Inc., (415) 293-4412,